Xu Chen

Xu Chen

Auto-generated profile, based on publicly available information

Xu Chen

Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SDStine Darkner
Stine Darkner
Jens Peter GoetzeJens Peter Goetze
Jens Peter Goetze
XCXu Chen
Xu Chen
KHKristoffer Mads Aaris Henningsen
Kristoffer Mads Aaris Henningsen
SPSteen Pehrson
Steen Pehrson
JSJesper Hastrup Svendsen
Jesper Hastrup Svendsen

1 October 2004 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
BNBrian Nilsson
Brian Nilsson
XCXu Chen
Xu Chen
SPSteen Pehrson
Steen Pehrson
HJHelle Lone Jensen
Helle Lone Jensen
LSLars Sondergaard
Lars Sondergaard
JSJesper Hastrup Svendsen
Jesper Hastrup Svendsen

10 March 2016 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
QJQi Jin
Qi Jin
SPSteen Pehrson
Steen Pehrson
PJPeter Karl Jacobsen
Peter Karl Jacobsen
XCXu Chen
Xu Chen

1 March 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
QJQi Jin
Qi Jin
PJPeter Karl Jacobsen
Peter Karl Jacobsen
SPSteen Pehrson
Steen Pehrson
XCXu Chen
Xu Chen

1 October 1994 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Open access
XCXu Chen
Xu Chen
MBMartin Borggrefe
Martin Borggrefe
AMAntonio Martinez-Rubio
Antonio Martinez-Rubio
CHChristine Hief
Christine Hief
WHWilhelm Haverkamp
Wilhelm Haverkamp
GBGünter Breithardt
Günter Breithardt
In a prospective randomized study, we assessed the electrophysiologic effects and the efficacy of ajmaline versus propafenone in patients with accessory pathways (APs). During initiated atrioventricular (AV) reentrant tachycardia or atrial fibrillation (AF), ajmaline (1 mg/kg as bolus followed by infusion of 15 micrograms/kg/min) or propafenone (2 mg/kg, followed by infusion of 30 micrograms/kg/min.) were randomly administered intravenously (i.v.) in 40 patients with APs. AV reentrant tachycardia terminated in 15 of 16 patients (94%) on ajmaline and in 12 of 15 patients (80%, NS) on propafenone. AF ceased in 4 of 4 patients receiving ajmaline and in 3 of 5 patients receiving propafenone (n.s.). During continuous infusion of drugs, AV reentrant tachycardia became noninducible in 10 (50%) patients receiving ajmaline, as compared with 6 (32%) receiving propafenone (NS). Both drugs significantly prolonged the anterograde and retrograde effective refractory periods (ERPs) of the AP. There were no significant differences in changes in electrophysiologic parameters between the two drugs. Ajmaline and propafenone are highly effective and safe in terminating and preventing reinitiation of AV reentrant tachycardia or AF in patients with APs. Both drugs significantly prolonged the anterograde and retrograde ERPs of the APs.

1 September 2017 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
CLChangjian Lin
Changjian Lin
SPSteen Pehrson
Steen Pehrson
PJPeter Karl Jacobsen
Peter Karl Jacobsen
XCXu Chen
Xu Chen